TY - JOUR
T1 - Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab
AU - Ogata, Atsushi
AU - Umegaki, Noriko
AU - Katayama, Ichiro
AU - Kumanogoh, Atsushi
AU - Tanaka, Toshio
N1 - Funding Information:
NU, IK. AK and TT have no conflict interest. Funding: This study was supported by the Program for Promotion of Fundamental Studies in Health Sciences from the National Institute of Biomedical Innovation.
PY - 2012/1
Y1 - 2012/1
N2 - Psoriatic arthritis (PsA) is considered as one of the seronegative spondylarthropathies. Like rheumatoid arthritis (RA), the increased production of interleukin (IL)-6 suggests a pathogenic role of IL-6 in PsA. However, whether humanized anti-IL-6 receptor antibody such as tocilizumab (TCZ) might be effective for PsA as well as RA has yet to be determined. We report herein two cases of PsA treated using TCZ. Although, TCZ treatment resulted in disappearance of serum CRP in both patients, arthritis and skin lesions were not improved despite 6-month administration of TCZ. In contrast, tumor necrosis factor (TNF) inhibitor proved effective against arthritis and skin lesions in these patients. Collectively, these findings not only indicate that IL-6 has distinct pathological roles in RA and PsA, but also suggest that TNF inhibitor therapy (but not TCZ) is effective for arthritis and skin lesions of PsA.
AB - Psoriatic arthritis (PsA) is considered as one of the seronegative spondylarthropathies. Like rheumatoid arthritis (RA), the increased production of interleukin (IL)-6 suggests a pathogenic role of IL-6 in PsA. However, whether humanized anti-IL-6 receptor antibody such as tocilizumab (TCZ) might be effective for PsA as well as RA has yet to be determined. We report herein two cases of PsA treated using TCZ. Although, TCZ treatment resulted in disappearance of serum CRP in both patients, arthritis and skin lesions were not improved despite 6-month administration of TCZ. In contrast, tumor necrosis factor (TNF) inhibitor proved effective against arthritis and skin lesions in these patients. Collectively, these findings not only indicate that IL-6 has distinct pathological roles in RA and PsA, but also suggest that TNF inhibitor therapy (but not TCZ) is effective for arthritis and skin lesions of PsA.
KW - Psoriatic Arthritis
KW - Tocilizumab
UR - http://www.scopus.com/inward/record.url?scp=84855716888&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855716888&partnerID=8YFLogxK
U2 - 10.1016/j.jbspin.2011.06.011
DO - 10.1016/j.jbspin.2011.06.011
M3 - Article
C2 - 21962389
AN - SCOPUS:84855716888
VL - 79
SP - 85
EP - 87
JO - Joint Bone Spine
JF - Joint Bone Spine
SN - 1297-319X
IS - 1
ER -